Early-onset pancreatic cancer: Clinical characteristics and survival outcomes.

[1]  M. Scartozzi,et al.  BRCA-mutant pancreatic ductal adenocarcinoma , 2021, British Journal of Cancer.

[2]  M. Gonen,et al.  Treatment patterns and survival in patients with early‐onset pancreatic cancer , 2021, Cancer.

[3]  C. Iacobuzio-Donahue,et al.  Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. , 2021, Journal of the National Cancer Institute.

[4]  N. Sasahira,et al.  Neoadjuvant gemcitabine and nab‐paclitaxel for borderline resectable pancreatic cancers: Intention‐to‐treat analysis compared with upfront surgery , 2020, Journal of hepato-biliary-pancreatic sciences.

[5]  Xing Liu,et al.  Worse prognosis in young patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy , 2020, Medicine.

[6]  H. Eguchi,et al.  Characteristics of early‐onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes , 2020, Annals of gastroenterological surgery.

[7]  A. Rogers,et al.  Clinicopathological features and oncological outcomes of patients with young‐onset rectal cancer , 2020, The British journal of surgery.

[8]  H. Zhang,et al.  Young age increases the risk for lymph node metastasis in patients with early Colon Cancer , 2019, BMC Cancer.

[9]  R. Andersson,et al.  Early-onset pancreatic cancer: a population-based study using the SEER registry , 2019, Langenbeck's Archives of Surgery.

[10]  A. Jemal,et al.  Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. , 2019, The Lancet. Public health.

[11]  Amit Merchea,et al.  Rising Proportion of Young Individuals With Rectal and Colon Cancer , 2018, Clinical colorectal cancer.

[12]  D. V. Von Hoff,et al.  NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. , 2019, European journal of cancer.

[13]  G. Honda,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.

[14]  S. Leach,et al.  Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter? , 2019, Clinical Cancer Research.

[15]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[16]  K. Brennan,et al.  Disease Characteristics, Clinical Management, and Outcomes of Young Patients With Colon Cancer: A Population‐based Study , 2018, Clinical colorectal cancer.

[17]  A. Maitra,et al.  High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer , 2018, Cancer Prevention Research.

[18]  R. Feakins,et al.  Demographic, clinical, and pathological features of early onset pancreatic cancer patients , 2018, BMC Gastroenterology.

[19]  Yongping Zhou,et al.  Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[20]  Jin‐Young Jang,et al.  Clinicopathologic and survival differences in younger patients with pancreatic ductal adenocarcinoma-A propensity score-matched comparative analysis. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[21]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[22]  T. Fujii,et al.  Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society , 2016, Pancreas.

[23]  S. Yachida,et al.  Germline mutations in Japanese familial pancreatic cancer patients , 2016, Oncotarget.

[24]  S. Yachida,et al.  Clinicopathologic Features and Germline Sequence Variants in Young Patients (⩽40 Years Old) With Pancreatic Ductal Adenocarcinoma , 2016, Pancreas.

[25]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[26]  W. Bamlet,et al.  Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis , 2016, Pancreas.

[27]  H. Imaoka,et al.  Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study , 2016, Pancreas.

[28]  Li Wei,et al.  Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis12 , 2016, Translational oncology.

[29]  S. Nunobe,et al.  Clinicopathological features of gastric cancer in young patients , 2016, Gastric Cancer.

[30]  G. Costamagna,et al.  Early onset pancreatic cancer: risk factors, presentation and outcome. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[31]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[32]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[33]  K. Hemminki,et al.  Familial risk of early and late onset cancer: nationwide prospective cohort study , 2012, BMJ : British Medical Journal.

[34]  J. Cameron,et al.  Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts , 2012, Journal of Gastrointestinal Surgery.

[35]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[36]  Y. Kitagawa,et al.  Retrospective analysis of prognostic outcome of gastric cancer in young patients , 2011, International Journal of Clinical Oncology.

[37]  H. Ueno,et al.  A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer , 2009, British Journal of Cancer.

[38]  C. Benz.  Impact of aging on the biology of breast cancer. , 2005, Critical reviews in oncology/hematology.

[39]  P. Maisonneuve,et al.  Early Onset Pancreatic Cancer: Evidence of a Major Role for Smoking and Genetic Factors , 2007, Cancer Epidemiology Biomarkers & Prevention.

[40]  M. Spitz,et al.  An epidemiologic study of early onset lung cancer. , 2006, Lung cancer.